Should I buy Boston Scientific (BSX) stock or is it too late?

Boston Scientific · Health Care · price $43

See the full Boston Scientific (BSX) profile

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Citigroup — 67% of its targets hit on this sector (516 calls tested). It aims for $48 (+11 %), call made on October 6, 2026, maturing on October 6, 2027 (8 d ago).

The 10 reliable analysts $56+29 %

The 9 other firms $70+62 %

How to read it: the 10 reliable firms are not filtered by optimism — 10 aim above the price, 0 below, hence their $56 median. “The 9 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Boston Scientific

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Stifel	88 %	+36.7 %	17	$65 +50%
TD Cowen	100 %	+31.8 %	5	$56 +29%
Citigroup	92 %	+30.8 %	24	$48 +11%
RBC Capital	83 %	+25.5 %	18	$70 +62%
Needham	74 %	+18.8 %	27	$57 +32%
Canaccord Genuity	80 %	+17.9 %	15	$66 +52%
Barclays	72 %	+17.8 %	18	$48 +11%
UBS	75 %	+16.4 %	8	$67 +55%

In short — Should you invest in Boston Scientific? Is it too late, still worth it? Analysts are fairly positive (76% buy, median target $65, i.e. +50%), and the most reliable on BSX targets even higher. But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

76% of analysts rate it a buy (Buy consensus, 21 ratings) — a sign of market conviction.
Median price target $65, i.e. +50% from the current price ($43).
The most reliable firm on BSX, Mizuho (100% hit rate, 4 scored calls), targets $70 (call made on July 15, 2026, maturing on July 15, 2027) (+62%) in its most recent call.
7 analysts rated reliable (≥55% hit rate, beat their sector) are bullish on the stock.
Reasonable valuation (P/E ~18) relative to its sector.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 21 ratings, 5 are neutral.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.

The analyst consensus on BSX

Median target $65 (+50%) · 21 ratings · Buy consensus

Strong Buy00%

Buy1676%

Hold524%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Boston Scientific now?

We won't decide for you. The facts: 76% of analysts rate it a buy, median target $65 (+50%), and Mizuho (most reliable on BSX, 100%) targets $70. Weigh that against valuation (P/E ~18). This is not personalized advice.

Is it too late to invest in Boston Scientific?

Not according to analysts: the median target ($65) is still +50% above the current price ($43) (most reliable on BSX: Mizuho, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Boston Scientific still worth investing in?

It depends on the gap between the price ($43) and its estimated value: analysts target $65 on median (+50%), with 76% buys (most reliable on BSX: Mizuho, 100%). Cross-check with their real reliability on BSX and the cautions above. Information, not advice.

What's the main risk in buying BSX?

The consensus is not unanimous: of 21 ratings, 5 are neutral.

→ Go deeper: the full Boston Scientific profile (consensus, analyst reliability, price target, performance).